Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300716 · ClinicalTrials.gov registry record · Phase 2
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00300716 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 82 participants.
The verdict
NCT00300716, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
This study is designed to determine whether memantine is an effective treatment for memory and cognitive problems associated with multiple sclerosis when compared to placebo.
Interventions
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2004-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300716
The ClinicalTrials.gov registry entry for NCT00300716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Memantine is the first listed.
NCT00300716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00300716 about?
NCT00300716 is a clinical study titled "Trial of Memantine for Cognitive Impairment in Multiple Sclerosis". This study is designed to determine whether memantine is an effective treatment for memory and cognitive problems associated with multiple sclerosis when compared to placebo.
What is the current status of trial NCT00300716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2004-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00300716?
The interventions under investigation include: Memantine (DRUG).
Who is sponsoring clinical trial NCT00300716?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.